[1] J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int. J. Cancer, 127 (2010) 2893–2917. https://doi.org/10.1002/ijc.25516
[2] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin. 68 (2018) 394–424. https://doi.org/10.3322/caac.21492
[3] Y. Isobe, A. Nashimoto, K. Akazawa, I. Oda, K. Hayashi, I. Miyashiro, H. Katai, S. Tsujitani, Y. Kodera, Y. Seto, M. Kaminishi, Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry, Gastric Cancer, 14 (2011) 301–316. https://doi.org/10.1007/s10120-011-0085-6
[4] Y. Lei, X. Xin, D. Morgan, J.E. Pintar, L.D. Fricker, Identification of mouse CPX-1, a novel member of the metallocarboxypeptidase gene family with highest similarity to CPX-2, DNA Cell Biol. 18 (1999) 175–185. https://doi.org/10.1089/104454999315565
[5] Y.H. Kim, H.M. O'Neill, J.P. Whitehead, Carboxypeptidase X-1 (CPX-1) is a secreted collagen-binding glycoprotein, Biochem. Biophys. Res. Commun. 468 (2015) 894–899. https://doi.org/10.1016/j.bbrc.2015.11.053
[6] E.J. Chang, H.B. Kwak, H. Kim, J.C. Park, Z.H. Lee, H.H. Kim, Elucidation of CPX-1 involvement in RANKL-induced osteoclastogenesis by a proteomics approach, FEBS Lett. 564 (2004) 166–70. https://doi.org/10.1016/S0014-5793(04)00338-2
[7] Y.H. Kim, J.L. Barclay, J. He, X. Luo, H.M. O'Neill, S. Keshvari, J.A. Webster, C. Ng, L.J. Hutley, J.B. Prins, J.P. Whitehead, Identification of carboxypeptidase X (CPX)-1 as a positive regulator of adipogenesis, FASEB J. 30 (2016) 2528–2540. https://doi.org/10.1096/fj.201500107R
[8] Y. Zhang, Y. Lin, J. Duan, K. Xu, M. Mao, X. Wang, A population-based analysis of distant metastasis in stage iv gastric cancer, Med. Sci. Monit. 26 (2020) 1–18. https://doi.org/10.12659/MSM.923867
[9] J. Liu, L. Jiang, J. Liu, T. He, Y. Cui, F. Qian, P. Yu, AEBP1 promotes epithelial-mesenchymal transition of gastric cancer cells by activating the NF-ΚB pathway and predicts poor outcome of the patients, Sci. Rep. 8 (2018) 1–13. https://doi.org/10.1038/s41598-018-29878-6
[10] G. Niu, Y. Yang, J. Ren, T. Song, Z. Hu, L. Chen, R. Hong, J. Xia, C. Ke, X. Wang, Overexpression of CPXM2 predicts an unfavorable prognosis and promotes the proliferation and migration of gastric cancer, Oncol. Rep. 42 (2019) 1283–1294. https://doi.org/10.3892/or.2019.7254
[11] S.E. Reznik , L.D. Fricker, Carboxypeptidases from A to Z: Implications in embryonic development and Wnt binding, Cell. Mol. Life Sci. 58 (2001) 1790–1804. https://doi.org/10.1007/PL00000819
[12] S.L. Schissel, S.E. Dunsmore, X. Liu, R.W. Shine, M.A. Perrella, M.D. Layne, Aortic carboxypeptidase-like protein is expressed in fibrotic human lung and its absence protects against bleomycin-induced lung fibrosis, Am. J. Pathol. 174 (2009) 818–828. https://doi.org/10.2353/ajpath.2009.080856
[13] R.R. Valiathan, M. Marco, B. Leitinger, C.G. Kleer, R. Fridman, Discoidin domain receptor tyrosine kinases: New players in cancer progression, Cancer Metastasis Rev. 31 (2012) 295–321. https://doi.org/10.1007/s10555-012-9346-z
[14] S.H. Lo , L.B. Chen, Focal adhesion as a signal transduction organelle, Cancer Metastasis Rev. 13 (1994) 9–24. https://doi.org/10.1007/BF00690415
[15] F.G. Giancotti, G. Tarone, Positional control of cell fate through joint integrin/receptor protein kinase signaling, Annu. Rev. Cell Dev. Biol. 19 (2003) 173–206. https://doi.org/10.1146/annurev.cellbio.19.031103.133334
[16] R.O. Hynes, Integrins: bidirectional, allosteric signaling machines, Cell. 110 (2002) 673–687. https://doi.org/10.1016/s0092-8674(02)00971-6